Can a tailored drug cocktail beat lung cancer recurrence?
Disease control
Recruiting now
This phase 3 trial is testing whether adding an extra immunotherapy drug (tremelimumab) and more chemotherapy to the standard treatment (durvalumab) can lower the amount of cancer DNA found in the blood of people with stage III non-small cell lung cancer. The study enrolls 48 par…
Phase: PHASE3 • Sponsor: Maximilian Diehn • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC